NIH Triage

The Scientist, Oct. 17, 1994, page 13) concerning my commentary "Triage At NIH: A Smoke Screen Concealing The Real Problems Facing American Science" (The Scientist, Sept. 5, 1994, page 13) contains some interesting news, but also some unsubstantiated statements. I was glad to learn that the National Institute of Mental Health (NIMH) has changed the triage procedures regarding communication with the applicants, who now will receive th

Written byJose Musacchio
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

It is good to know that the plans were changed, and that the applicants will receive the reviewers' full comments. The bad news is that the change will impose an even higher burden on the study-section members, who now must write their reviews in an objective editorial style, suitable for consumption by deeply disappointed applicants. In the good old days, reviewers who do not write well, like me, relied on the editorial abilities and good judgment of the scientific-review administrators. It is obvious that to write the critiques in final form will require more time and effort, no matter what Stamper says. However, this problem has been neglected, perhaps because reviewers are not paid for their writing time. Despite the reviewers' increase in work, applicants whose proposals are deemed NC will not receive a summary of the IRG discussions. This can hardly be considered an advantage for the applicants, but ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies